Sensitive detection of somatic mutations in GC-rich cancer gene promoters
NAR Cancer · 08.04.2026 · 8 (2)
DOI: 10.1093/narcan/zcag011 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 04.05.2026. Verfasst von Meifang Qi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129 Boston, MA, United States. Hauptthemen laut MEDLINE: Promoter Regions, Genetic, Mutation, Breast Neoplasms, GC Rich Sequence. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Broad Institute SPARC, Quadrangle Fund for Advancing and Seeding Translational Research.
Abstract (Originalsprache)
Somatic mutations in protein-coding genes and noncoding regulatory regions are the major drivers of cancer. Only a relatively small number of somatic noncoding mutations that are likely drivers have been described to date, including those in the promoters of the TERT, FOXA1, and TP53 genes. The impact of these alterations can be profound by initiating, increasing, or abolishing gene expression. Promoter mutations in particular have been difficult to identify even from whole tumor genomes due to their high content of G and C nucleotides, which leads to loss of sequencing coverage in these regions. Therefore, the landscape of somatic drivers in gene promoters remains incomplete. Here, we present a hybrid capture assay optimized for >3000 promoters of cancer genes. We show that this assay allows for deep sequencing of challenging GC-rich promoter regions, enabling discovery of reliable point mutations, short insertions and deletions, copy number variants, and mutational signatures in cell line models as well as formalin-fixed, paraffin-embedded archival tissue samples. Our assay nominated candidate noncoding driver mutations in CDK4, SMAD3, and GATA3 in breast cancer for future functional follow-up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Krantz Family Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA 02129 Boston, MA, United States.
- Harvard Medical School Department of Medicine, Boston, MA 02115, United States.
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
- Broad Clinical Laboratories, LLC, Burlington, MA 01803, United States.
- Twist Bioscience South San Francisco, California, CA 94080, United States.
- Ludwig Center at Harvard, Boston, MA 02115, United States.
ORCID-Profile: Esther Rheinbay
Förderung
- NCI NIH HHS
- Broad Institute SPARC
- Quadrangle Fund for Advancing and Seeding Translational Research
- Slim Initiative in Genomic Medicine for the Americas
- Carlos Slim Foundation in Mexico
Zitieren
APA
Qi, M., Dave, P. S., Francis, N., DeFelice, M., Pollock, S., Corbitt, H., Mitsiades, I. R., Wang, G., Frere, P., Fox, A., Khitrov, G., Petersen, C., Larkin, K., Hamilton, S., Ellisen, L. W., Gulhan, D. C., Hidalgo-Miranda, A., Lennon, N., Cibulskis, C., & Rheinbay, E. (2026). Sensitive detection of somatic mutations in GC-rich cancer gene promoters. NAR Cancer, 8(2). https://doi.org/10.1093/narcan/zcag011
Vancouver
Qi M, Dave PS, Francis N, DeFelice M, Pollock S, Corbitt H, et al. Sensitive detection of somatic mutations in GC-rich cancer gene promoters. NAR Cancer. 2026;8(2). doi:10.1093/narcan/zcag011
BibTeX
@article{Qi2026,
author = {Qi, Meifang and Dave, Preshita Sanjay and Francis, Nicole and DeFelice, Matthew and Pollock, Sam and Corbitt, Holly and Mitsiades, Irene Rin and Wang, Gengchao and Frere, Paul and Fox, Alan and Khitrov, Gregory and Petersen, Caroline and Larkin, Katie and Hamilton, Susanna and Ellisen, Leif W and Gulhan, Doga C and Hidalgo-Miranda, Alfredo and Lennon, Niall and Cibulskis, Carrie and Rheinbay, Esther},
title = {Sensitive detection of somatic mutations in GC-rich cancer gene promoters},
journal = {NAR Cancer},
year = {2026},
volume = {8},
number = {2},
doi = {10.1093/narcan/zcag011}
}
EUVIMED